Elimination of HCV as a public health concern among people who inject drugs by 2030 – What will it take to get there?
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
Introduction: Globally, there is a considerable burden of HCV and HIV infections among people who inject drugs (PWID) and transmission of both infections continues. Needle and syringe programme (NSP) and opioid substitution therapy (OST) coverage remains low, despite evidence demonstrating their prevention benefit. Direct‐acting antiviral therapies (DAA) with HCV cure >95% among PWID provide an opportunity to reverse rising trends in HCV‐related morbidity and mortality and reduce incidence. However, HCV testing, linkage to care, and treatment remain low due to health system, provider, societal, and patient barriers. Between 2015 and 2030, WHO targets include reducing new HCV infections by 80% and HCV deaths by 65%, and increasing HCV diagnoses from <5% to 90% and number of eligible persons receiving HCV treatment from <1% to 80%. This commentary discusses why PWID should be considered as a priority population in these efforts, reasons why this goal could be attainable among PWID, challenges that need to be overcome, and key recommendations for action. Discussion: Challenges to HCV elimination as a global health concern among PWID include poor global coverage of harm reduction services, restrictive drug policies and criminalization of drug use, poor access to health services, low HCV testing, linkage to care and treatment, restrictions for accessing DAA therapy, and the lack of national strategies and government investment to support WHO elimination goals. Key recommendations for action include reforming drug policies (decriminalization of drug use and/or possession, or providing alternatives to imprisonment for PWID; decriminalization of the use and provision of sterile needles‐syringes; and legalization of OST for people who are opioid dependent), scaling up and improving funding for harm reduction services, making health services accessible for PWID, supporting community empowerment and community‐based programmes, improving access to affordable diagnostics and medicines, and eliminating stigma, discrimination, and violence against PWID. Conclusions: The ambitious targets for HCV elimination set by WHO are achievable in many countries, but will require researchers, healthcare providers, policy makers, affected communities, advocates, the pharmaceutical and diagnostics industries, and governments around the world to work together to make this happen.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence
Mattick, R. P., Breen, C., Kimber, J., & Davoli, M. (2009) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002209.pub2 · Cited by 1,654
Degenhardt, L., Bucello, C., Mathers, B., Briegleb, C., Ali, H., Hickman, M., & McLaren, J. (2011) · Addiction · doi:10.1111/j.1360-0443.2010.03140.x · Cited by 856 · cited 1×
“Mortality among opioid dependent people is 14 times higher than that among people of the same age and sex [102], driven by drug-related harm and HCV-related liver disease [30].”
BackgroundBarua, S., Greenwald, R., Grebely, J., Dore, G. J., Swan, T., & Taylor, L. E. (2015) · Annals of Internal Medicine · doi:10.7326/m15-0406 · Cited by 401 · cited 1×
“Restrictions for accessing DAA therapy To reduce the budget impact of high-price DAA therapies, governments in many countries are restricting access to DAA therapy based on fibrosis stage, recent drug use, and prescriber type [100,115,116].”
BackgroundSelf-citationAspinall, E. J., Nambiar, D., Goldberg, D. J., Hickman, M., Weir, A., Van Velzen, E., Palmateer, N., Doyle, J. S., Hellard, M. E., & Hutchinson, S. J. (2014) · International Journal of Epidemiology · doi:10.1093/ije/dyt243 · Cited by 399
Hagan, H., Pouget, E. R., & Des Jarlais, D. C. (2011) · Journal of Infectious Diseases · doi:10.1093/infdis/jir196 · Cited by 313
Topp, L., Iversen, J., Conroy, A., Salmon, A. M., & Maher, L. (2008) · Australian and New Zealand Journal of Public Health · doi:10.1111/j.1753-6405.2008.00163.x · Cited by 56
Mortality in a large community-based cohort of inner-city residents in Vancouver, Canada
Deans, G. D., Raffa, J. D., Lai, C., Fischer, B., Krajden, M., Amin, J., Walter, S. R., Dore, G. J., Grebely, J., & Tyndall, M. W. (2013) · CMAJ Open · doi:10.9778/cmajo.20130002 · Cited by 15
Self-citation
Cited by
Update on global epidemiology of viral hepatitis and preventive strategies
Jefferies, M., Rauff, B., Rashid, H., Lam, T., & Rafiq, S. (2018) · World Journal of Clinical Cases · doi:10.12998/wjcc.v6.i13.589 · Cited by 352
Metadata
- Authors
- Grebely, J., Dore, G. J., Morin, S., Rockstroh, J. K., & Klein, M. B.
- Venue
- Journal of the International AIDS Society
- Publisher
- Wiley
- Published
- 2017-01
- Volume
- 20
- Issue
- 1
- Pages
- 22146-22146
- ISSN
- 1758-2652 (ISSN-L)
- OpenAlex
- W2741725136
- Cited by
- 171
- References
- 7
- FWCI
- 12.47
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.